Illumina, Inc. (NASDAQ:ILMN) Stake Boosted by Robeco Institutional Asset Management B.V.

Robeco Institutional Asset Management B.V. boosted its holdings in Illumina, Inc. (NASDAQ:ILMN) by 74.1% in the third quarter, HoldingsChannel.com reports. The firm owned 276,506 shares of the life sciences company’s stock after acquiring an additional 117,730 shares during the period. Robeco Institutional Asset Management B.V.’s holdings in Illumina were worth $36,059,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also recently added to or reduced their stakes in ILMN. Primecap Management Co. CA raised its position in shares of Illumina by 462.5% during the 2nd quarter. Primecap Management Co. CA now owns 2,428,760 shares of the life sciences company’s stock worth $253,514,000 after purchasing an additional 1,997,010 shares during the period. Millennium Management LLC increased its position in Illumina by 305.0% in the second quarter. Millennium Management LLC now owns 1,485,599 shares of the life sciences company’s stock worth $155,067,000 after buying an additional 1,118,747 shares during the period. Capital World Investors lifted its stake in Illumina by 41.1% in the first quarter. Capital World Investors now owns 2,753,504 shares of the life sciences company’s stock valued at $378,111,000 after buying an additional 801,814 shares during the last quarter. Marshall Wace LLP acquired a new position in shares of Illumina during the second quarter valued at $77,628,000. Finally, Swedbank AB bought a new position in shares of Illumina during the first quarter worth about $99,682,000. Institutional investors own 89.42% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on ILMN. UBS Group lifted their price objective on shares of Illumina from $133.00 to $145.00 and gave the company a “neutral” rating in a research report on Tuesday. Leerink Partners lifted their price target on Illumina from $160.00 to $200.00 and gave the company an “outperform” rating in a report on Thursday, October 17th. Citigroup increased their price objective on Illumina from $155.00 to $190.00 and gave the stock a “buy” rating in a report on Tuesday. Stephens reaffirmed an “overweight” rating and set a $170.00 target price on shares of Illumina in a research note on Wednesday, July 10th. Finally, Argus raised Illumina from a “hold” rating to a “buy” rating and set a $150.00 price target for the company in a research note on Wednesday, August 28th. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating, fourteen have issued a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $161.50.

Illumina Trading Up 1.0 %

Shares of ILMN opened at $154.96 on Wednesday. The company has a current ratio of 1.11, a quick ratio of 0.86 and a debt-to-equity ratio of 1.04. Illumina, Inc. has a 1-year low of $89.00 and a 1-year high of $156.66. The stock has a market capitalization of $24.69 billion, a P/E ratio of -8.09 and a beta of 1.13. The business’s 50-day moving average price is $136.87 and its 200 day moving average price is $122.92.

Illumina (NASDAQ:ILMN) last released its earnings results on Monday, November 4th. The life sciences company reported $1.14 earnings per share for the quarter, topping the consensus estimate of $0.88 by $0.26. The business had revenue of $1.08 billion for the quarter, compared to the consensus estimate of $1.08 billion. Illumina had a negative net margin of 68.73% and a positive return on equity of 3.08%. The firm’s quarterly revenue was down 3.5% compared to the same quarter last year. During the same period last year, the firm posted $0.33 earnings per share. Analysts expect that Illumina, Inc. will post 3.62 earnings per share for the current year.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.